Inventor · disambiguated record
Lynn Dorothy Poulton
Also filed as: POULTON LYNN · POULTON LYNN DOROTHY
12 granted patents·9 pending applications·54 citations·filing 2009–2025
89Inventor score
Files withCEPHALON LLC7TEVA PHARMACEUTICALS AUSTRALIA PTY LTD7CEPHALON INC4CEPHALON AUSTRALIA PTY LTD1CLARKE ADAM WILLIAM1
Top patents by PatentIndex Score
21 records- 0195US10138296B2Antibodies that specifically bind to TL1ACEPHALON INC·Filed 2016·Granted Nov 27, 2018·17 cites·34 claims
- 0293US11220549B2Antibodies that specifically bind to TL1A and methods of treating respiratory tract diseasesCEPHALON INC·Filed 2018·Granted Jan 11, 2022·8 cites·31 claims
- 0390US10822422B2Antibodies against TL1a and uses thereofTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2016·Granted Nov 3, 2020·10 cites·13 claims
- 0489US11725052B2Anti-PAR-2 antibodies and methods of use thereofCEPHALON LLC·Filed 2021·Granted Aug 15, 2023·2 cites·26 claims
- 0587US2025353919A1Antibodies Against TL1A and Uses ThereofTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2025·Application pending·0 cites
- 0685US11267883B2Antibodies that specifically bind to human IL-15 and uses thereofCEPHALON INC·Filed 2017·Granted Mar 8, 2022·5 cites·27 claims
- 0785US8563697B2Anti-IL-12/IL-23 antibodiesCLARKE ADAM WILLIAM·Filed 2009·Granted Oct 22, 2013·11 cites·11 claims
- 0884US2025179202A1Antibodies That Specifically Bind to TL1A and Methods of Treating Skin DiseaseCEPHALON LLC·Filed 2024·Application pending·0 cites
- 0983US12410256B2Antibodies that specifically bind to TL1a and methods of treating gastrointestinal or lung diseasesTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2023·Granted Sep 9, 2025·0 cites·19 claims
- 1078US2024301076A1Anti-cxcr2 antibodies and uses thereofCEPHALON LLC·Filed 2024·Application pending·0 cites
- 1177US12384841B2Anti-PAR-2 antibodies and methods of use thereofCEPHALON LLC·Filed 2023·Granted Aug 12, 2025·0 cites·3 claims
- 1277US12162946B2Antibodies that specifically bind to TL1A and methods of treating gastrointestinal diseaseCEPHALON LLC·Filed 2021·Granted Dec 10, 2024·0 cites·31 claims
- 1375US11332534B2Anti-CXCR2 antibodies and uses thereofCEPHALON INC·Filed 2019·Granted May 17, 2022·1 cites·13 claims
- 1473US12018084B2Anti-CXCR2 antibodies and uses thereofCEPHALON LLC·Filed 2022·Granted Jun 25, 2024·0 cites·25 claims
- 1571US12410247B2Polynucleotides encoding antibodies that specifically bind to human IL-15CEPHALON LLC·Filed 2022·Granted Sep 9, 2025·0 cites·20 claims
- 1668US2021347904A1Antibodies against tl1a and uses thereofTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2020·Application pending·0 cites
- 1764US2014255302A1ANTIBODIES AGAINST TL1a AND USES THEREOFTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2014·Application pending·0 cites
- 1852US2014086922A1Anti-il-12/il-23 antibodiesCEPHALON AUSTRALIA PTY LTD·Filed 2013·Application pending·0 cites
- 1947US2016264661A1Anti-il-12/il-23 antibodiesTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2016·Application pending·0 cites
- 2042US2014286957A1ANTIBODIES TO CD1dTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2014·Application pending·0 cites
- 2136US2012282184A1Treatment of obesityWALDMANN HERMAN·Filed 2010·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →